Phase III ADVANCE: 96-Wk Primary Efficacy Analysis of DTG + FTC/(TAF or TDF) vs EFV/FTC/TDF in ART-Naive PWH in South Africa

July 6-10, 2020; Virtual
Noninferiority of first-line DTG-based vs EFV-based regimens maintained through Week 96, with significantly greater weight gain observed in PWH receiving DTG + FTC/TAF.
Format: Microsoft PowerPoint (.ppt)
File Size: 258 KB
Released: July 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Related Content

CCO commentary by Dr. Darcy Wooten on data presented at CROI 2021 regarding integrase strand inhibitor-associated weight gain and clinical implications

Darcy Wooten, MD Released: May 5, 2021

Download free expert-authored slides to see how clinicians use HIV-ASSIST to choose appropriate, guideline-based antiretroviral therapy

Jehan Budak, MD Ethel D. Weld, MD, PhD Released: April 26, 2021

Free expert slides from Clinical Care Options (CCO) reviewing the use of HIV-ASSIST for ART and LTBI treatment selection in a patient with HIV

Nicky Mehtani, MD, MPH Released: April 26, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue